

**ANNOUNCEMENT  
SUMMARY OF MINUTES  
ANNUAL GENERAL MEETING OF SHAREHOLDERS  
AND  
EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS  
PT PYRIDAM FARMA Tbk.**

The Board of Directors of PT Pyridam Farma Tbk. (hereinafter referred to as the “**Company**”) hereby informs to the Shareholders of the Company that it has held the Annual General Meeting of Shareholders (hereinafter referred to as the “**AGMS**”) and Extraordinary General Meeting Of Shareholders (hereinafter referred to as the “**EGMS**”) (AGMS and EGMS are hereinafter jointly referred to as “**Meeting**”) based on the Financial Services Authority (“**OJK**” or *Otoritas Jasa Keuangan*) Regulation No. 16/POJK.04/2020 dated April 20, 2020 regarding the Implementation of the General Meeting of Holders of a Public Company Electronically and OJK Regulation No. 15/POJK.04/2020 dated April 20, 2020 regarding The Planning and Procedures for General Meeting of Shareholders of Public Companies, which are as follows:

**A. The Meeting was held on:**

|          |   |   |
|----------|---|---|
| Day/Date | : | Thursday, July 28 <sup>th</sup> , 2022  |
| Time     | : | 2.02 p.m. to 3.13 p.m. Jakarta time   |
| Venue    | : | Sinarmas MSIG Tower, 12th floor, Jl. Jend. Sudirman No. Kav. 21, Kuningan, South Jakarta, Indonesia |

**Meeting Agenda:**

**AGMS**

1. Approval of the Annual Report and Ratification of the Company's Financial Statements for the financial year ended on December 31, 2021 as well as granting of full release and discharge of responsibilities (*volledig acquit et de charge*) to the members of the Board of Directors and members of the Board of Commissioners for the management and supervisory actions carried out for the financial year ended on December 31, 2021;
2. Determination of the allocation of the Company's net profit for the financial year ended on December 31, 2021;
3. Determination of Remuneration of Members of the Board of Directors and Board of Commissioners of the Company for the Financial Year in 2022;
4. Appointment of Public Accountant Firm to perform audit on the Company's Consolidated Financial Statements for the financial year ended on December 31, 2022;
5. Reports on the implementation of the use of fund from the Public Offering of Pyridam Farma Bonds I Year 2020 and Pyridam Farma Continuous Bond I Phase I Year 2022;
6. Discussion of feasibility studies on (i) additional business activities of the Manufacture of Other Plastic Goods YTDL (KBLI 22299) and (ii) carrying out business activities that have been regulated in the Company's Articles of Association but have not been carried out previously, namely Manufacture of Non-Clinical Laboratory Equipment, Pharmaceutical and Health from Glass (KBLI 23122) and Manufacture of Clinical Laboratory Equipment of Glass (KBLI 23124); and

**HEAD OFFICE**

Sinarmas MSIG Tower 12th Floor  
Jl. Jend. Sudirman Kav. 21  
Jakarta 12920 - Indonesia

**P** +62-21-50991067

**FACTORY**

Hanjawar, Pacet,  
Cianjur 43253 – Indonesia

**P** +62-263-580-833  
**F** +62-263-582-290



7. Approval of amendments to Article 3 of the Company's Articles of Association concerning the Purpose and Objectives as well as the Company's Business Activities in the form of additional business activities of Manufacture of Other Plastic Goods YTDL (KBLI 22299) and the abolition of Manufacture of Animal Pharmaceutical Products (KBLI 21013).

## AGMS

Approval of (i) the Company's plan in regards to the acquisitions of PT Ethica Industri Farmasi ("EIF"), a company established under the laws of the Republic of Indonesia, which resulted in a change of control in EIF by way of the purchase of all shares owned by EIF's shareholders by the Company (either directly or indirectly) which constitutes all of issued and paid up shares in EIF (the "Transaction Plan"), which the Proposed Transaction will be a Material Transaction as regulated in FSA Regulation No. 17/POJK.04/2020 on Material Transactions and Changes in Business Activities; and (ii) the draft deed of acquisition or the deed of sale and purchase of shares, with terms and conditions deemed favorable by the Company and the shareholders of EIF in accordance with the provisions of the applicable laws and regulations.

- B. Members of the Board of Commissioners and the Board of Directors of the Company who were physically present at the Meeting :

### BOARD OF COMMISSIONERS :

Independent Commissioner : CHARLES D. MARPAUNG  
Independent Commissioner : MAURA LINDA SITANGGANG  
Independent Commissioner : MOHAMMAD SYAMSUL ARIFIN

### BOARD OF DIRECTORS :

President Director : LEE YAN GWAN  
Director : WIDJANARKO BRODOSAPUTRO  
Director : YENFRINO GUNADI

- C. Members of the Board of Commissioners of the Company who were present virtually at the Meeting:

### BOARD OF COMMISSIONERS :

President Commissioner : ROBBY YULIANTO

- D. The AGMS was attended by **359.744.112** shares with valid voting rights or equivalent to **67.23 %** from the total shares with valid voting rights issued by the Company.
- E. The AGMS was attended by **359.700.912** shares with valid voting rights or equivalent to **67.22 %** from the total shares with valid voting rights issued by the Company.
- F. In the Meeting, each Shareholder/Proxy was given the opportunity to ask questions and/or provide opinions, related to each Meeting agenda.
- G. The decision-making mechanism in the Meeting is as follows:  
Meeting decisions were made by way of deliberation to reach consensus, if there were shareholders or their proxies who vote against or abstain, the voting would be held.

#### HEAD OFFICE

Sinarmas MSIG Tower 12th Floor  
Jl. Jend. Sudirman Kav. 21  
Jakarta 12920 - Indonesia

P +62-21-50991067

#### FACTORY

Hanjawar, Pacet,  
Cianjur 43253 - Indonesia

P +62-263-580-833  
F +62-263-582-290



Certificate ID05/0646

[pyfa.co.id](http://pyfa.co.id)

H. The number of Shareholders/Proxies who asked questions and/or provided opinions as well as the results of the Voting on each agenda of the AGMS are as follows:

| AGMS Agenda | The number of Shareholders/Proxies who asked questions and/or provide opinions | Voting Results                                |            |         |
|-------------|--|---|------------|---------|
|             |  | Affirmative                                   | Dissenting | Abstain |
| 1           | 0  | 359.744.112 shares<br>(100% of those present) | 0          | 0       |
| 2           | 0  | 359.744.112 shares<br>(100% of those present) | 0          | 0       |
| 3           | 0  | 359.744.112 shares<br>(100% of those present) | 0          | 0       |
| 4           | 0  | 359.744.112 shares<br>(100% of those present) | 0          | 0       |
| 5           | 0  | 359.744.112 shares<br>(100% of those present) | 0          | 0       |
| 6           | 0  | 359.744.112 shares<br>(100% of those present) | 0          | 0       |
| 7           | 0  | 359.744.112 shares<br>(100% of those present) | 0          | 0       |

I. The number of Shareholders/Proxies who asked questions and/or provided opinions as well as the results of the Voting on each agenda of the EGMS are as follows:

| EGMS Agenda | The number of Shareholders/Proxies who asked questions and/or provide opinions | Voting Results                                |            |         |
|-------------|--|---|------------|---------|
|             |  | Affirmative                                   | Dissenting | Abstain |
| 1           | 0  | 359.700.912 shares<br>(100% of those present) | 0          | 0       |

**HEAD OFFICE**

Sinarmas MSIG Tower 12th Floor  
Jl. Jend. Sudirman Kav. 21  
Jakarta 12920 - Indonesia

P +62-21-50991067

**FACTORY**

Hanjawar, Pacet,  
Cianjur 43253 - Indonesia

P +62-263-580-833  
F +62-263-582-290



[pyfa.co.id](http://pyfa.co.id)

J. Whereas in the Company's Meeting the following decisions have been made:

**AGMS**

**I. First AGMS Agenda**

1. Approved the Annual Report and ratify the Company's Financial Statements for the financial year ended on December 31 2021;
2. Upon the approval of the Company's Annual Report including the Board of Commissioners' Duties Report for the Financial Year ended on December 31, 2021 and the ratification of the Company's Consolidated Financial Year ended on December 31, 2021 has been audited by the Tanubrata Sutanto Fahmi Bambang & Partners Public Accounting Firm, member firm of BDO International with fair opinion, in all material respects, the Meeting gave full discharge (*volledig acquit et de charge*) to all members of the Board of Directors and Board of Commissioners for the management and supervisory actions that have been carried out during the Financial Year ended on December 31, 2021, to the extent that such action is not a criminal act and such action is reflected in the Consolidated Financial Report, and the Company's Annual Report for Financial Year ended on December 31, 2021.

**II. Second AGMS Agenda**

Approved the use of the Company's Net Profit for the financial year ended on December 31, 2021 in the amount of IDR 5.478.944.087,- (five billion four hundred seventy eight million nine hundred forty four thousand and eighty seven Rupiah) which will be allocated to reserve funds and working capital of the Company.

**III. Third AGMS Agenda**

Granted authority and power to the Board of Commissioners of the Company to determine the amount of salary or honorarium and other allowances for the members of the Board of Commissioners and Board of Directors of the Company for the financial year ended on December 31, 2022, based on the Decision of the Meeting of the Board of Commissioners of the Company with total salary, honorarium, bonuses, and other allowances for the Board of Directors and the Board of Commissioners while taking into consideration of the financial conditions and performance of the Company.

**IV. Fourth AGMS Agenda**

Granted power to the Board of Commissioners to determine the Public Accounting Firm that will audit the Company's Financial Statements which will end on December 31, 2022 by considering the proposal of the Board of Commissioners of the Company and taking into account the recommendations of the Audit Committee of the Company and authorizing the Board of Directors of the Company to determine the amount of honorarium for the public accountant and other requirements, considering that the Company still needs time to monitor and assess performance and consider prospective public accountants to be appointed based on input from the Board of Commissioners of the Company and the Audit Committee of the Company and consider other objectives deemed necessary in making decisions.

**HEAD OFFICE**

Sinarmas MSIG Tower 12th Floor  
Jl. Jend. Sudirman Kav. 21  
Jakarta 12920 - Indonesia

**P** +62-21-50991067

**FACTORY**

Hanjawar, Pacet,  
Cianjur 43253 – Indonesia

**P** +62-263-580-833

**F** +62-263-582-290



## V. Fifth AGMS Agenda

1. Approved the report on the realization of the use of proceeds from the public offering of Pyridam Farma I Obligation Year 2020 as of December 31, 2021 which is IDR 292.112.573.338 (two hundred twenty-nine billion one hundred twelve million five hundred seventy-three thousand and three hundred thirty-eight Rupiah) as referred to in the Report on Realization of the Use of Proceeds from the Public Offering of Pyridam Farma Bonds I Year 2020 No. 005/PYFA-CS/I/2022, dated January 10, 2022.
2. Approved the report on the realization of the use of proceeds from the public offering of Pyridam Farma Continuous Bond I Phase I Year 2022 as of June 30, 2022 which is IDR 58,500,000,000 (fifty eight billion five hundred million Rupiah) as referred to in the Report on Realization of the Use of Proceeds from the Public Offering of Pyridam Farma Continuous Bond I Phase I Year 2022 No. 052/PYFA-CS/VII/2022, dated July 12, 2022.

## VI. Sixth AGMS Agenda

Approved the discussion of the feasibility study on (i) additional business activities of the Manufacture of Other Plastic Goods YTDL (KBLI 22299) and (ii) carrying out business activities that have been regulated in the Company's Articles of Association but have not been carried out previously, namely Manufacture of Non-Clinical Laboratory Equipment, Pharmaceutical and Health from Glass (KBLI 23122) and Manufacture of Clinical Laboratory Equipment of Glass (KBLI 23124).

## VII. Seventh AGMS Agenda

1. Approved the amendments Article 3 of the Company's Articles of Association concerning the Purpose and Objectives as well as the Company's Business Activities in the form of additional business activities of the Manufacture of Other Plastic Goods YTDL (KBLI 22299) and the abolition of the Manufacture of Animal Pharmaceutical Products (KBLI 21013).
2. Granted power and authority to the Board of Directors with substitution rights to restate in a Notarial Deed and take all necessary actions related to the resolutions of this Meeting agenda, including compiling all provisions of the Articles of Association in a Notarial Deed (if necessary) and submitting it to any authorized governmental institution to obtain a receipt for notification of changes to the Articles of Association, do everything that is deemed necessary and useful for that purpose with nothing being excluded, including making additions and/or changes to the amendments to the Articles of Association if this is required by the authorized governmental institution.

## EGMS EGMS Agenda

1. Approved the Company's plan in regards to the acquisitions plan of PT Ethica Industri Farmasi ("EIF"), which resulted in a change of control in EIF by way of the purchase of all shares owned by EIF's shareholders by the Company which constitutes all or most of the shares that have been issued and paid up in EIF and also the subscription of new shares by the Company which will be issued by EIF.

### HEAD OFFICE

Sinarmas MSIG Tower 12th Floor  
Jl. Jend. Sudirman Kav. 21  
Jakarta 12920 - Indonesia

P +62-21-50991067

### FACTORY

Hanjawar, Pacet,  
Cianjur 43253 - Indonesia

P +62-263-580-833  
F +62-263-582-290



2. Approved the draft of deed of acquisition or the deed of sale and purchase of shares, with terms and conditions deemed favorable by the Company and the shareholders of EIF in accordance with the provisions of the applicable laws and regulations.
3. Granted power of attorney with substitution rights to the Board of Directors of the Company to take all the actions in connection with the above-mentioned Decisions of this Meeting including but not limited to make, sign, and submit all documents and/or deeds, to appear before anyone where necessary, provide information in connection with the above-mentioned decisions.

**Jakarta, August 1, 2021**  
**The Board of Directors of PT Pyridam Farma Tbk.**

**HEAD OFFICE**

Sinarmas MSIG Tower 12th Floor  
Jl. Jend. Sudirman Kav. 21  
Jakarta 12920 - Indonesia

**P** +62-21-50991067

**FACTORY**

Hanjawar, Pacet,  
Cianjur 43253 – Indonesia

**P** +62-263-580-833  
**F** +62-263-582-290



[pyfa.co.id](http://pyfa.co.id)